Pulmonary Fibrosis

TMC is a major participant in the Mary Katherine Gelmacher Pulmonary Fibrosis Research Program at the University of Missouri at Kansas City (UMKC) Lung Research Center.  Pulmonary Fibrosis is the formation of excess fibrous connective tissue in the lungs, commonly described as “scarring of the lung.” It is estimated that up to 200,000 Americans have pulmonary fibrosis, and the disease is responsible for more than 40,000 deaths a year.  

“Unfortunately, there is currently no effective drug treatment of pulmonary fibrosis,” says Gary A. Salzman, MD, director of the UMKC Lung Research Center. “We have been doing research on pulmonary fibrosis at the Center for the last decade and have made great strides in investigating potential therapies to prevent scarring after an injury to the lung.”

If you have been diagnosed with pulmonary fibrosis and would like to participate in the study, please send an email request to pulmonaryfibrosis@tmcmed.org